Hasil Pencarian - Juleen Gayed
Anda harus masuk terlebih dahulu
- Menampilkan 1 - 3 hasil dari 3
-
1
Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial oleh Juleen Gayed, Vishva Bangad, Xia Xu, Federico Mensa, Mark Cutler, Özlem Türeci, Uǧur Şahin, Kayvon Modjarrad, Kena A. Swanson, Annaliesa S. Anderson, Alejandra Gurtman, Nicholas Kitchin
Diterbitkan 2024-07-01Dapatkan teks lengkap
Artikel -
2
Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial oleh Juleen Gayed, Oyeniyi Diya, Francine S. Lowry, Xia Xu, Vishva Bangad, Federico Mensa, Jing Zou, Xuping Xie, Yanping Hu, Claire Lu, Mark Cutler, Todd Belanger, David Cooper, Kenneth Koury, Annaliesa S. Anderson, Özlem Türeci, Uǧur Şahin, Kena A. Swanson, Kayvon Modjarrad, Alejandra Gurtman, Nicholas Kitchin
Diterbitkan 2024-01-01Dapatkan teks lengkap
Artikel -
3
Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination oleh Timothy E. Albertson, Caitlin Hansen, Smiti Bihari, Juleen Gayed, Xia Xu, J. Abraham Simón-Campos, Michael E. Dever, Jose F. Cardona, Essack Mitha, Jeffrey B. Baker, Georgina Keep, Islamiat Oladipupo, Federico J. Mensa, Ye Feng, Hua Ma, Kenneth Koury, Susan Mather, Claudia Ana Ianos, Annaliesa S. Anderson, Özlem Türeci, Uǧur Şahin, William C. Gruber, Alejandra Gurtman, Charu Sabharwal, Nicholas Kitchin, the C4591031, C4591007 Clinical Trial Groups
Diterbitkan 2024-03-01Dapatkan teks lengkap
Artikel